| Trial ID: | L0128 |
| Source ID: | NCT00096915
|
| Associated Drug: |
Darbepoetin Alfa
|
| Title: |
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Disease|Chronic Kidney Disease
|
| Interventions: |
DRUG: Darbepoetin Alfa
|
| Outcome Measures: |
Primary: The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL and less than or equal to 13.0 g/dL during the evaluation phase, entire study | Secondary: Hb values over the duration of the study, entire study|Darbepoetin alfa doses over the duration of the study, entire study|Frequency and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure, entire study
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
110
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-10
|
| Completion Date: |
2005-11
|
| Results First Posted: |
|
| Last Update Posted: |
2009-05-22
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00096915
|
